---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-003677"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:34:39.467674+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCardia completes low-dose enrollment in CardiALLO allogeneic MSC HFrEF trial

## Summary
- Enrolled and dosed 3 patients in low-dose cohort (20M cells) of Phase I/II CardiALLO trial.
- Trial is first prospective allogeneic MSC study targeting HFrEF patients with elevated heart stress/inflammation markers.
- DSMB safety review expected March 2025; next dose escalation (100M cells) to follow.
- Used Morph DNA steerable guide for enhancing cell delivery during treatment procedures.
- Program aims to support pivotal US studies and conditional time-limited approval in Japan.

## SEC filing metadata
- accession: 0001437749-25-003677
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925003677/0001437749-25-003677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925003677/bcda20250213_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-003677
- JSON: https://secwatch.observer/filing/0001437749-25-003677.json
- Plain text: https://secwatch.observer/filing/0001437749-25-003677.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.